Clinical Trial Update: A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158) [Phase 1]

View source ↗

Summary

Phase 1 trial of extended-release niacin/laropiprant in adolescents with heterozygous familial hypercholesterolemia was terminated; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypercholesterolemia
• Heterozygous Familial Hypercholesterolemia

Drugs mentioned

• Extended-release Niacin/Laropiprant (MK-0524A) (niacin/laropiprant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hypercholesterolemia, Familial, Heterozygous Familial Hypercholesterolemia | Phase 1 | Status: TERMINATED | Results posted: 2013-12-04